{"id":251490,"date":"2024-01-09T00:00:00","date_gmt":"2024-01-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epibon0004-biopharma-egfr-epidemiology-mature-markets\/"},"modified":"2026-04-25T05:14:09","modified_gmt":"2026-04-25T05:14:09","slug":"epibon0004-biopharma-egfr-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epibon0004-biopharma-egfr-epidemiology-mature-markets\/","title":{"rendered":"EGFR &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of epidermal growth factor receptor (<abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>)-mutated tumors comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated cancer for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>The patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 43 <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated non-small-cell lung cancer (<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>).<\/li>\n<li>Diagnosed incident cases of metastatic <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of nonmetastatic <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by exon subtype (exon 18 \/ 19 \/ 20 \/ 21).<\/li>\n<li>Diagnosed first-line drug-treatable cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated breast cancer.<\/li>\n<li>Diagnosed recurrent incident cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated colorectal cancer.<\/li>\n<li>Diagnosed incident cases of metastatic <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated squamous cell carcinoma of the head and neck (<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>).<\/li>\n<li>Diagnosed incident cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated small-cell lung cancer (<abbr title=\"small-cell lung cancer\">SCLC<\/abbr>).<\/li>\n<li>Diagnosed incident cases of nonmetastatic <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated colorectal cancer.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>-mutated glioblastoma.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251490","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251490\/revisions"}],"predecessor-version":[{"id":294347,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251490\/revisions\/294347"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}